GlobeNewswire by notified

BBS-Bioactive Bone Substitutes Plc: Managers' Transactions - Pekka Jalovaara

Share

BBS-Bioactive Bone Substitutes Plc, Company announcement, Management transactions, 7 December 2023 at 7.00 p.m. (EET)

BBS-Bioactive Bone Substitutes Oyj - Managers' Transactions – Pekka Jalovaara

____________________________________________

Person subject to the notification requirement
Name: Jalovaara Pekka
Position: Member of the Board/Deputy member
Issuer: BBS Bioactive Bone Substitutes Oyj
LEI: 743700BYSBP0PCR6N767
Notification type: INITIAL NOTIFICATION
Reference number: 743700BYSBP0PCR6N767_20231207173757_8

____________________________________________

Transaction date: 2023-12-04
Venue not applicable
Instrument type: FINANCIAL INSTRUMENT LINKED TO A SHARE OR A DEBT INSTRUMENT
ISIN: FI4000260583
Nature of the transaction: DISPOSAL

Transaction details
(1): Volume: 133,850 Unit price: 0.005 EUR

Aggregated transactions
(1): Volume: 133,850 Volume weighted average price: 0.005 EUR

____________________________________________

Transaction date: 2023-12-05
Venue not applicable
Instrument type: FINANCIAL INSTRUMENT LINKED TO A SHARE OR A DEBT INSTRUMENT
ISIN: FI4000260583
Nature of the transaction: DISPOSAL

Transaction details
(1): Volume: 46,150 Unit price: 0.0038 EUR

Aggregated transactions
(1): Volume: 46,150 Volume weighted average price: 0.0038 EUR

____________________________________________

Transaction date: 2023-12-06
Venue not applicable
Instrument type: FINANCIAL INSTRUMENT LINKED TO A SHARE OR A DEBT INSTRUMENT
ISIN: FI4000260583
Nature of the transaction: DISPOSAL

Transaction details
(1): Volume: 5,227 Unit price: 0.002801 EUR

Aggregated transactions
(1): Volume: 5,227 Volume weighted average price: 0.002801 EUR

For more information, please contact:

Juliusz Rakowski, CEO
+358 50 448 5132
juliusz.rakowski@bbs-artebone.fi

Certified Advisor:
Nordic Certified Adviser AB,
+46 70 551 67 29,
info@certifiedadviser.se

BBS in brief

BBS -Bioactive Bone Substitutes Plc is a orthobiology company that started its operations in 2003. We have developed a new product for the treatment of complex bone fractures and bone healing issues. Our goal is to provide next-generation medical products for the treatment of bone injuries in orthopedic surgery. In the pharmaceutical industry, the development and research work require perseverance and courage to innovate. We have a track record of over 20 years in this field. Our company is characterized by expertise, innovation, and dedicated employees who are passionate about their work. Our first developed product, ARTEBONE® Paste, is in the final stages of the CE marking process to enable its commercialization in the EU market. We are based in Oulu with a medical manufacturing facility in Reisjärvi, holding a manufacturing license. The company's headquarters are in Oulu, and we employ over 20 people.

BBS has been listed on Nasdaq First North Growth Market Finland since February 2018.

More information: www.bbs-artebone.fi

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Swedish city court judgement fulfilled by M3CS21.2.2024 15:45:42 CET | Press release

Company announcement no. 4/2024 Reference is made to the judgement rendered by the Swedish city court on 24 January 2024 in favour of Columbus in which the court held that the company M3CS AB and its founders had acted unlawfully and were liable to pay damages and costs to Columbus in the range of SEK 43-45m. All parties’ subsequently appealed the judgement. On the date hereof, M3CS AB has fulfilled the judgement by payment of SEK 44,801,607 to Columbus and M3CS AB has withdrawn the appeal proceedings. It is expected that the founders of M3CS AB also will withdraw their appeal as a consequence of M3CS AB’s fulfilment of the judgement. Subject to the parties’ completion of the formal procedure to cancel the appeal case in Sweden, which will include a cancellation of the appeal by Columbus, the judgement of the Swedish court will thus be final. Ib Kunøe Søren Krogh Knudsen Chairman of the Board CEO & President For further information, please contact: CEO & President, Søren Krogh Knudsen,

Bank of Åland Plc: The 2023 Annual Report of the Bank of Åland Plc has been published21.2.2024 15:05:00 CET | Press release

Bank of Åland Plc Annual Financial Report February 21, 2024, 16.05 EET The 2023 Annual Report of the Bank of Åland Plc has been published The Annual Report for 2023 of the Bank of Åland Plc (Ålandsbanken Abp) including the corporate governance report for 2023 was published today in Swedish and English. The Compensation Report and the Capital and Risk Management Report were published as separate documents at the same time. The financial reports in Swedish are being published in compliance with European Single Electronic Format (ESEF) reporting requirements. In line with ESEF requirements, the primary portions of the consolidated financial statements have been marked up with XBRL tags. The authorised public accounting company KPMG Oy has provided an independent auditors’ affidavit of reasonable assurance about the Bank of Åland Plc’s ESEF financial statements. The Annual Report, the Compensation Report and the Capital and Risk Management Report are available for downloading in PDF format

Ålandsbankens årsredovisning för 2023 har publicerats21.2.2024 15:05:00 CET | Pressemelding

Ålandsbanken Abp Årsredovisning 21.2.2024 kl. 16.05 EET Ålandsbankens årsredovisning för 2023 har publicerats Ålandsbankens årsredovisning inklusive bolagsstyrningsrapport 2023 har i dag publicerats på svenska och engelska. Samtidigt publicerades Ersättningsrapporten och Kapital- och riskhanteringsrapporten som separata dokument. De finansiella rapporterna på svenska publiceras i enlighet med rapporteringskraven för European Single Electronic Format (ESEF). I linje med ESEF-kraven har de primära delarna i koncernbokslutet markerats med XBRL-taggar. Revisionsbyrån KPMG Oy Ab har tillhandahållit en oberoende revisors försäkran med rimlig säkerhet om Ålandsbanken Abps ESEF-bokslut. Årsredovisningen, Ersättningsrapporten och Kapital- och riskhanteringsrapporten finns att ladda ner på vår webbplats: Årsredovisning https://www.alandsbanken.fi/uploads/pdf/result/7437006WYM821IJ3MN73-2023-12-31-sv.zip https://www.alandsbanken.fi/uploads/pdf/result/arsredovisn2023sv.pdf Ersättningsrapport https

Kreditbanken A/S: Årsrapport 202321.2.2024 15:04:26 CET | pressemeddelelse

Regnskabsmeddelelse for 2023 Overskud på 191 mio. kr. før skat Kreditbanken har i 2023 realiseret et historisk stort resultat før skat på 191 mio. kr. Resultatet svarer til den præcisering af forventningen til resultatet, som banken meddelte Nasdaq Copenhagen A/S den 5. januar 2024. I 2022 var resultatet før skat på 55,2 mio. kr. Bestyrelsen indstiller til generalforsamlingen, at der udbetales 100 kr. pr. aktie. i udbytte. 2023 i overskrifter Et historisk stort resultat før skat på 191,0 mio. kr. Netto rente- og gebyrindtægter på 302,6 mio. kr. mod 229,6 mio. kr. i 2022 Positive kursreguleringer på 47,8 mio. kr. mod negative kursreguleringer på 33,5 mio. kr. i 2022 Udgifter til personale og administration på 141,7 mio. kr. mod 122,3 mio. kr. i 2022 Af- og nedskrivninger på materielle aktiver på 1,7 mio. kr. mod 9,9 mio. kr. i 2022 Nedskrivninger på udlån og hensættelser på garantier og kredittilsagn på 17,3 mio. kr. mod 9,0 mio. kr. i 2022. Indtjening pr. omkostningskrone på 2,19 Indlå

Notice for the Annual General Meeting of Novo Nordisk A/S21.2.2024 15:03:24 CET | Press release

Bagsværd, Denmark, 21 February 2024 – The Annual General Meeting of Novo Nordisk A/S will be held on: Thursday 21 March 2024 at 14.00 (CET) The Annual General Meeting is held as a partially electronic general meeting. Accordingly, shareholders can choose between participating in person at Bella Center, Center Boulevard 5, DK-2300 Copenhagen S, Denmark or participating virtually via an IT application. We encourage shareholders to exercise their rights by submitting proxies or votes by correspondence in advance of the Annual General Meeting. Also, Novo Nordisk offers the possibility of viewing the Annual General Meeting via live webcast on Novo Nordisk’s website. Please refer to the notice for further information. The notice for the Annual General Meeting, including Appendix: Candidates for the Board of Directors, is enclosed. BOARD OF DIRECTORS All Board members elected by the Annual General Meeting are up for election. The Board of Directors proposes re-election of Helge Lund as chair

HiddenA line styled icon from Orion Icon Library.Eye